Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.736
5-Year Impact Factor – 2.135
Index Copernicus  – 168.52
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2015, vol. 24, nr 5, September-October, p. 801–806

doi: 10.17219/acem/29183

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Assessment of Vitamin D Level in Autoimmune Thyroiditis Patients and a Control Group in the Polish Population

Adam Maciejewski1,A,B,C,D,F, Marlena Wójcicka2,B, Magdalena Roszak3,C, Jacek Losy4,A,E, Katarzyna Łącka5,A,F

1 Student’s Scientific Society, Section of Endocrinology, Poznan University of Medical Sciences, Poland

2 Department of Clinical Neuroimmunology, Poznan University of Medical Sciences, Poland

3 Department of Computer Science and Statistics, Poznan University of Medical Sciences, Poland

4 Department of Clinical Neuroimmunology, Poznan University of Medical Sciences, Neuroimmunological Unit, Institute of Experimental and Clinical Medicine, Polish Academy of Sciences, Poland

5 Department of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, Poland

Abstract

Background. Vitamin D, known for its role in calcium-phosphorus homeostasis, is also a significant immunomodulatory factor. Vitamin D deficiency has been reported in some autoimmune disorders. Recently, vitamin D level in autoimmune thyroiditis (HT – Hashimoto’s thyroiditis) has become the subject of researchers’ interest.
Objectives. This study aims to assess vitamin 25-OH-D3 levels in HT patients in comparison to a control group in the Polish population. This would be the first attempt conducted in this region with such poor sunlight exposure.
Material and Methods. The group we studied consisted of 62 subjects diagnosed with HT (mean age 49.15 ± 15.51) and 32 healthy controls matched with age and sex (mean age 46.09 ± 14.32). All blood samples were collected in the first quarter of the year to minimize the impact of seasonal fluctuations of vitamin D concentrations.
Results. In the HT group the mean vitamin D level was 20.09 nmol/L (SD ± 12.66), compared to 30.31 nmol/L (SD ± 19.49) in the controls, p = 0.014. None of the patients and the controls was vitamin D sufficient (75–125 nmol/L). The deficiency (< 50 nmol/L) was significantly more common among HT patients compared to the controls (61–98.4% vs. 27– 84.4%, p = 0.029).
Conclusion. In conclusion, we found that serum vitamin D concentration is significantly lower in HT patients in comparison to the control group. This suggests vitamin D deficit as one of the risk factors for HT development. Observed vitamin D level was also low in the control group, therefore wider supplementation in general population should be recommended.

Key words

vitamin D, vitamin D deficiency, autoimmunity, Hashimoto’s disease

References (31)

  1. Tunbridge WM, Vanderpump MP: Population screening for autoimmune thyroid disease. Endocrinol Metab Clin North Am 2000, 29, 239–253.
  2. Zaletel K, Gaberšček S: Hashimoto’s Thyroiditis: From Genes to the Disease. Curr Genomics 2011, 12, 576–588.
  3. Brix TH, Hegedüs L: Twins as a tool for evaluating the influence of genetic susceptibility in thyroid autoimmunity. Ann Endocrinol (Paris) 2011, 72, 103–107.
  4. Eschler DC, Hasham A, Tomer Y: Cutting edge: the etiology of autoimmune thyroid diseases. Clin Rev Allergy Immunol 2011, 41, 190–197.
  5. Christakos S, Hewison M, Gardner DG, Wagner CL, Sergeev IN, Rutten E, Pittas AG, Boland R, Ferrucci L, Bikle DD: Vitamin D: beyond bone. Ann N Y Acad Sci, 2013, 1287, 45–58.
  6. Pierrot-Deseilligny C, Rivaud-Péchoux S, Clerson P, de Paz R, Souberbielle JC: Relationship between 25-OH-D serum level and relapse rate in multiple sclerosis patients before and after vitamin D supplementation. Ther Adv Neurol Disord 2012, 5, 187–198.
  7. Zipitis CS, Akobeng AK: Vitamin D supplementation in early childhood and risk of type 1 diabetes: a systematic review and meta-analysis. Arch Dis Child 2008, 93, 512–517.
  8. Płudowski P, Karczmarewicz E, Bayer M, Carter G, Chlebna-Sokół D, Czech-Kowalska J, Dębski R, Decsi T, Dobrzańska A, Franek E, Głuszko P, Grant WB, Holick MF, Yankovskaya L, Konstantynowicz J, Książyk JB, Księżopolska-Orłowska K, Lewiński A, Litwin M, Lohner S, Lorenc RS, Lukaszkiewicz J, Marcinowska-Suchowierska E, Milewicz A, Misiorowski W, Nowicki M, Povoroznyuk V, Rozentryt P, Rudenka E, Shoenfeld Y, Socha P, Solnica B, Szalecki M, Tałałaj M, Varbiro S, Żmijewski MA: Practical guidelines for
  9. Chen S, Sims GP, Chen XX, Gu YY, Chen S, Lipsky PE: Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol 2007, 179, 1634–1647.
  10. Griffin MD, Lutz W, Phan VA, Bachman LA, McKean DJ, Kumar R: Dendritic cell modulation by 1alpha, 25 dihydroxyvitamin D3 and its analogs: a vitamin D receptordependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc Natl Acad Sci USA 2001, 98, 6800–6805.
  11. Sloka S, Silva C, Wang J, Yong VW: Predominance of Th2 polarization by vitamin D through a STAT6 dependent mechanism. J Neuroinflammation 2011, 8, 56.
  12. Figueroa-Vega N, Alfonso-Pérez M, Benedicto I, SánchezMadrid F, González-Amaro R, Marazuela M: Increased circulating pro-inflammatory cytokines and Th17 lymphocytes in Hashimoto’s thyroiditis. J Clin Endocrinol Metab 2010, 95, 953–962.
  13. Joshi S, Pantalena LC, Liu XK, Gaffen SL, Liu H, Rohowsky-Kochan C, Ichiyama K, Yoshimura A, Steinman L, Christakos S, Youssef S: 1,25-dihydroxyvitamin D(3) ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A. Mol Cell Biol 2011, 31, 3653–3669.
  14. Kamen DL, Tangpricha V: Vitamin D and molecular actions on the immune system: modulation of innate and autoimmunity. J Mol Med (Berl) 2010, 88, 441–450.
  15. Cantorna MT, Munsick C, Bemiss C, Mahon BD: 1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J Nutr 2000, 130, 2648–2652.
  16. Van Etten E, Branisteanu DD, Overbergh L, Bouillon R, Verstuyf A, Mathieu C: Combination of a 1,25 dihydroxyvitamin D3 analog and a bisphosphonate prevents experimental autoimmune encephalomyelitis and preserves bone. Bone 2003, 32, 397–404.
  17. Cantorna MT, Hayes CE, DeLuca HF: 1,25-Dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis. J Nutr 1998, 128, 68–72.
  18. Zella JB, McCary LC, DeLuca HF: Oral administration of 1,25-dihydroxyvitamin D3 completely protects NOD mice from insulin-dependent diabetes mellitus. Arch Biochem Biophys 2003, 417, 77–80.
  19. Tamer G, Arik S, Tamer I, Coksert D: Relative vitamin D insufficiency in Hashimoto’s thyroiditis. Thyroid 2011, 21, 891–896.
  20. Bozkurt NC, Karbek B, Ucan B, Sahin M, Cakal E, Ozbek M, Delibasi T: The Association Between Severity of Vitamin D Deficiency and Hashimoto’s Thyroiditis. Endocr Pract 2013, 19, 479–484.
  21. Kivity S, Agmon-Levin N, Zisappl M, Shapira Y, Nagy EV, Dankó K, Szekanecz Z, Langevitz P, Shoenfeld Y: Vitamin D and autoimmune thyroid diseases. Cell Mol Immunol 2011, 8, 243–247.
  22. Camurdan OM, Döğer E, Bideci A, Celik N, Cinaz P: Vitamin D status in children with Hashimoto thyroiditis. J Pediatr Endocrinol Metab 2012, 25, 467–470.
  23. Goswami R, Marwaha RK, Gupta N, Tandon N, Sreenivas V, Tomar N, Ray D, Kanwar R, Agarwal R: Prevalence of vitamin D deficiency and its relationship with thyroid autoimmunity in Asian Indians: a community-based survey. Br J Nutr 2009, 102, 382–386.
  24. Effraimidis G, Badenhoop K, Tijssen JG, Wiersinga WM: Vitamin D deficiency is not associated with early stages of thyroid autoimmunity. Eur J Endocrinol 2012, 167, 43–48.
  25. Andersen R, Brot C, Jakobsen J, Mejborn H, Mølgaard C, 331 Skovgaard LT, Trolle E, Tetens I, Ovesen L: Seasonal changes in vitamin D status among Danish adolescent girls and elderly women: the influence of sun exposure and vitamin D intake. Eur J Clin Nutr 2013, 67, 270–274.
  26. Napiórkowska L, Budlewski T, Jakubas-Kwiatkowska W, Hamzy V, Gozdowski D, Franek E: Prevalence of low serum vitamin D concentration in an urban population of elderly women in Poland. Pol Arch Med Wewn 2009, 11, 699–703.
  27. Garanty-Bogacka B, Syrenicz M, Goral J, Krupa B, Syrenicz J, Walczak M, Syrenicz A: Serum 25-hydroxyvitamin D (25-OH-D) in obese adolescents. Endokrynol Pol 2011, 62, 506–511.
  28. Kmieć P, Żmijewski M, Waszak P, Sworczak K, Lizakowska-Kmieć M: Vitamin D deficiency during winter months among an adult, predominantly urban, population in Northern Poland. Endokrynol Pol 2014, 65, 105–113.
  29. Andersen R, Mølgaard C, Skovgaard LT, Brot C, Cashman KD, Chabros E, Charzewska J, Flynn A, Jakobsen J, Kärkkäinen M, Kiely M, Lamberg-Allardt C, Moreiras O, Natri AM, O’brien M, Rogalska-Niedzwiedz M, Ovesen L: Teenage girls and elderly women living in northern Europe have low winter vitamin D status. Eur J Clin Nutr 2005, 59, 533–541.
  30. Schilling S: Epidemic vitamin D deficiency among patients in an elderly care rehabilitation facility. Dtsch Arztebl Int 2012, 109, 33–38.
  31. Pludowski P, Holick MF, Pilz S, Wagner CL, Hollis BW, Grant WB, Shoenfeld Y, Lerchbaum E, Llewellyn DJ, Kienreich K, Soni M: Vitamin D effects on musculoskeletal health, immunity, autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, dementia and mortality – a review of recent evidence. Autoimmun Rev 2013, 12, 976–989.
© Wroclaw Medical University